Page 1 | Search Results | Hematology, ASH Education Program

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.

https://doi.org/10.1182/hematology.2019000030

Published: 2019

Journal Articles

Long-term complications in adolescent and young adult leukemia survivors

K. Scott Baker, Karen L. Syrjala

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 146–153.

https://doi.org/10.1182/asheducation-2018.1.146

Published: 2018

Journal Articles

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

Andrés José María Ferreri

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 565–577.

https://doi.org/10.1182/asheducation-2017.1.565

Published: 2017

Journal Articles

Management of multiple myeloma in the newly diagnosed patient

María-Victoria Mateos, Jesús F. San Miguel

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 498–507.

https://doi.org/10.1182/asheducation-2017.1.498

Published: 2017

Journal Articles

Toward personalized treatment in Waldenström macroglobulinemia

Jorge J. Castillo, Steven P. Treon

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 365–370.

https://doi.org/10.1182/asheducation-2017.1.365

Published: 2017

Journal Articles

Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment

Flora E. van Leeuwen, Andrea K. Ng

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 323–330.

https://doi.org/10.1182/asheducation-2016.1.323

Published: 2016

Journal Articles

How should we treat newly diagnosed multiple myeloma patients?

María-Victoria Mateos, Jesús F. San Miguel

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 488–495.

https://doi.org/10.1182/asheducation-2013.1.488

Published: 2013

Journal Articles

Evidence-Based Mini-Review: The Role of Alkylating Agents in the Initial Treatment of Chronic Lymphocytic Leukemia Patients with the 11q Deletion

Wei Ding, Alessandra Ferrajoli

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 90–92.

https://doi.org/10.1182/asheducation-2010.1.90

Published: 2010

Journal Articles

Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment

John Radford

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 321–325.

https://doi.org/10.1182/asheducation-2008.1.321

Published: 2008

Journal Articles

New Agents in the Treatment of CLL

Susan O’Brien

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 457–464.

https://doi.org/10.1182/asheducation-2008.1.457

Published: 2008

Journal Articles

Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia

Jens Pedersen-Bjergaard, Morten T. Andersen, Mette K. Andersen

Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 392–397.

https://doi.org/10.1182/asheducation-2007.1.392

Published: 2007

Journal Articles

Current and Investigational Therapies for Patients with CLL

William G. Wierda

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 285–294.

https://doi.org/10.1182/asheducation-2006.1.285

Published: 2006

Journal Articles

Controversies in Follicular Lymphoma: “Who, What, When, Where, and Why?” (Not Necessarily in That Order!)

Myron S. Czuczman

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 303–310.

https://doi.org/10.1182/asheducation-2006.1.303

Published: 2006

Journal Articles

The Ubiquitin Proteasome Pathway from Bench to Bedside

Robert Z. Orlowski

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 220–225.

https://doi.org/10.1182/asheducation-2005.1.220

Published: 2005

Journal Articles

POEMS Syndrome

Angela Dispenzieri

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 360–367.

https://doi.org/10.1182/asheducation-2005.1.360

Published: 2005

Journal Articles

Amyloidosis and Waldenström’s Macroglobulinemia

Morie A. Gertz, Giampaolo Merlini, Steven P. Treon

Hematology Am Soc Hematol Educ Program (2004) 2004 (1): 257–282.

https://doi.org/10.1182/asheducation-2004.1.257

Published: 2004

Journal Articles

Low-Grade Lymphoma

Jane N. Winter, Randy D. Gascoyne, Koen Van Besien

Hematology Am Soc Hematol Educ Program (2004) 2004 (1): 203–220.

https://doi.org/10.1182/asheducation-2004.1.203

Published: 2004

NARROW

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Long-term complications in adolescent and young adult leukemia survivors

Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents

Management of multiple myeloma in the newly diagnosed patient

Toward personalized treatment in Waldenström macroglobulinemia

Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment

How should we treat newly diagnosed multiple myeloma patients?

Evidence-Based Mini-Review: The Role of Alkylating Agents in the Initial Treatment of Chronic Lymphocytic Leukemia Patients with the 11q Deletion

Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment

New Agents in the Treatment of CLL

Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia

Current and Investigational Therapies for Patients with CLL

Controversies in Follicular Lymphoma: “Who, What, When, Where, and Why?” (Not Necessarily in That Order!)

The Ubiquitin Proteasome Pathway from Bench to Bedside

POEMS Syndrome

Amyloidosis and Waldenström’s Macroglobulinemia

Low-Grade Lymphoma

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only